MAP2K7 and cancer: With regards to clinical evaluation of the combination of CDK4/6 and MEK inhibition in patients with cancer, there was a phase Ib in unselected adult patients with solid tumors that did not observe any efficacy [38], while a case series of nine adult patients with solid tumor harboring CDK4/6 and MEK pathway alterations treated with CDK4/6 and MEK inhibitors noted some clinical benefit in approximately 50% of patients [39].